Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech...
Grünenthal Germany is now certified as a Great Place to Work® and a Great Start! company for apprentices. The company was awarded these two...
Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader ...
Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total...
Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štěpán Kráčala, who...
Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide ...
Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights...
Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA®...
Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of...
Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with...
Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the Grünenthal Group, announced today that the supplemental New Drug...
Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective ...
The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...
Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...
Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...
Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...
Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for ...
Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management...
Creative approaches to research by young scientists provide opportunity for new and challenging thinking to benefit patients who suffer from pain. To ...
Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate...
Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP)...
Grünenthal ha anunciado hoy que ha firmado un acuerdo con MSD (nombre comercial de Merck & Co., Inc., Kenilworth, N.J., EE.UU.) para la distribución, ...
Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for...
Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market ...
The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc.,...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.